New Real-World Evidence from Personalized Trials Calls for Rethinking the Standard of Care for Non-Responders to Autoimmune Therapies

Personalized trials help patients achieve major reductions in joint flares and concomitant Rx in 17 weeks, while delivering $11k average savings per non-responder annually